Drug guidance
Asciminib for Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after two or more tyrosine kinase inhibitors
Condition
Blood and Immune System
Cancer
6 February 2026
-
Published on 04 Jun 2025
Last Updated on 06 Feb 2026
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
Asciminib 20 mg and 40 mg tablets as monotherapy for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase whose disease is resistant and/or who are intolerant to two or more tyrosine kinase inhibitors.
Asciminib is not recommended for patients with T315I mutation.
Funding status
Asciminib 20 mg and 40 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.
MAF assistance does not apply to asciminib 100 mg tablet.
Clinical indication, subsidy class and MediShield Life claim limit for asciminib are provided in the Annex.